Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2016—ArcherDX, in partnership with Horizon Discovery Group, launched the Archer SureShot ALK, RET, ROS1 Fusion Control to benchmark greater confidence in gene fusion detection using Archer FusionPlex Panels. The reference control is composed of FFPE curls of homogeneously mixed, precisely defined cell lines that contain EML4-ALK, CCDC6-RET, and SLC34A2-ROS1 fusions.
March 2016—Beckman Coulter Diagnostics obtained a CE mark for and released its new Access TSH (3rd IS) assay for use with the company’s Access family of immunoassay systems. This assay is the next generation of the Access Hypersensitive hTSH and Access Fast hTSH assays for the quantitative determination of human thyroid stimulating hormone (TSH, thyrotropin) levels in human serum and plasma.
March 2016—Quest Diagnostics will offer clinical laboratory testing using Dako’s PD-L1 IHC 28-8 pharmDx qualitative test, an FDA-approved complementary in vitro diagnostic test for use in the detection of PD-L1 expression in formalin-fixed, paraffin-embedded melanoma tissue.
March 2016—Bio-Rad Laboratories announced that its D-100 System for A1c testing has obtained FDA clearance to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
February 2016—Foundation Medicine announced a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking and Analysis to advance precision medicine, improve clinical outcomes, and deliver enhanced value to the health care system in the treatment of patients with metastatic non-small cell lung cancer.
February 2016—Integrated DNA Technologies introduced PrimeTime Gene Expression Master Mix, an optimized enzyme mix for probe-based qPCR. PrimeTime qPCR Assays are available with a choice of dyes and quenchers, and the predesigned assays are backed by a performance guarantee. The Master Mix integrates into new and existing experimental workflows and is also compatible with all commercially available 5’ nuclease gene expression assays.
February 2016—Novogene and Illumina have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing technology. The companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.
February 2015—PerkinElmer launched its Vectra 3 automated, high-throughput quantitative pathology imaging system. This solution’s new seven-color multiplexing and visualization capabilities are designed to enable pathologists and oncologists conducting research to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.
February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
